205 related articles for article (PubMed ID: 31435866)
1. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.
McEvoy J; Gandhi SK; Rizio AA; Maher S; Kosinski M; Bjorner JB; Carroll B
Qual Life Res; 2019 Dec; 28(12):3303-3312. PubMed ID: 31435866
[TBL] [Abstract][Full Text] [Related]
2. Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.
Rekhi G; Tay J; Lee J
J Psychopharmacol; 2022 Feb; 36(2):183-190. PubMed ID: 34979813
[TBL] [Abstract][Full Text] [Related]
3. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
[No Abstract] [Full Text] [Related]
4. Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia.
McEvoy JP
J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846247
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
Patterson-Lomba O; Ayyagari R; Carroll B
BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cognitive performance in first-episode drug-naïve schizophrenia, bipolar II disorder, and major depressive disorder patients after treatment.
Tang C; Huang W; Tan Y; Liu Y; Zheng G; Li B; Chen W; Yang Y; Xu G; Li X; Xu C; Xie G; Liang J
BMC Psychiatry; 2024 Jun; 24(1):434. PubMed ID: 38862969
[TBL] [Abstract][Full Text] [Related]
7. Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.
Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37022752
[No Abstract] [Full Text] [Related]
8. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
[TBL] [Abstract][Full Text] [Related]
9. Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder.
Gardea-Resendez M; Taylor-Desir MJ; Romo-Nava F; Bond D; Vallender EJ; Cuellar-Barboza AB; Prieto ML; Nunez N; Veldic M; Ozerdem A; Singh B; Markota M; Colby CL; Coombes BJ; Biernacka JM; McElroy SL; Frye MA
J Clin Psychopharmacol; 2022 Mar-Apr 01; 42(2):159-162. PubMed ID: 35230047
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
Uludag K; Wang DM; Goodman C; Chen DC; Wang L; Zhang X
Asian J Psychiatr; 2021 Dec; 66():102877. PubMed ID: 34638091
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.
Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M
J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873
[TBL] [Abstract][Full Text] [Related]
12. Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder.
Rajan TM; Bharadwaj B; Rajkumar RP; Adole PS
Asian J Psychiatr; 2018 Feb; 32():92-98. PubMed ID: 29222987
[TBL] [Abstract][Full Text] [Related]
13. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
[No Abstract] [Full Text] [Related]
14. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
[TBL] [Abstract][Full Text] [Related]
15. Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder: a cross-sectional study.
Woo JM; Jeon HJ; Noh E; Kim HJ; Lee SW; Lee KK; Kim SH; Hong JP
Health Qual Life Outcomes; 2014 Dec; 12():188. PubMed ID: 25519704
[TBL] [Abstract][Full Text] [Related]
16. Defining utility values for patients with tardive dyskinesia.
Ayyagari R; Goldschmidt D; Zhou M; Ribalov R; Caroff SN; Leo S
Curr Med Res Opin; 2022 Mar; 38(3):401-407. PubMed ID: 35045768
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neurocognitive function in major depressive disorder, bipolar disorder, and schizophrenia in later life: A cross-sectional study of euthymic or remitted, non-demented patients using the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J).
Terachi S; Yamada T; Pu S; Yokoyama K; Matsumura H; Kaneko K
Psychiatry Res; 2017 Aug; 254():205-210. PubMed ID: 28476012
[TBL] [Abstract][Full Text] [Related]
18. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
Preskorn SH; Macaluso M
J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
[TBL] [Abstract][Full Text] [Related]
19. Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Bergman H; Soares-Weiser K
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000204. PubMed ID: 29341071
[TBL] [Abstract][Full Text] [Related]
20. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders.
Caroff SN; Leong SH; Roberts C; Berkowitz RM; Campbell EC
J Clin Psychopharmacol; 2020; 40(1):38-45. PubMed ID: 31834084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
